Literature DB >> 12093142

A case of Parkinsonism due to lithium intoxication: treatment with Pramipexole.

Carlo Dallocchio1, Paolo Mazzarello.   

Abstract

We report the case of a 72-year-old woman with bipolar disorder treated with lithium for over a year, who suddenly developed disabling Parkinsonism, apparently after a gastroenteric infection. On hospital admission lithium plasma levels were 3.7 mmol/l. After lithium discontinuation, plasma levels decreased to 0.7 mmol/l, but without resolution of neurological symptoms. Biperidene and levodopa-benserazide did not ameliorate her extrapyramidal symptoms. Pramipexole 0.25 mg TID improved dramatically the Parkinsonism and all neurological symptoms resolved in a few days. Copyright 2002 Published by Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12093142     DOI: 10.1054/jocn.2001.1033

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  4 in total

1.  Disabling Parkinsonism following brief exposure to lithium carbonate in amyotrophic lateral sclerosis.

Authors:  L Mazzini; G D Oggioni; N Nasuelli; S Servo; L Testa; F Monaco
Journal:  J Neurol       Date:  2010-09-19       Impact factor: 4.849

2.  Lithium suppression of tau induces brain iron accumulation and neurodegeneration.

Authors:  P Lei; S Ayton; A T Appukuttan; S Moon; J A Duce; I Volitakis; R Cherny; S J Wood; M Greenough; G Berger; C Pantelis; P McGorry; A Yung; D I Finkelstein; A I Bush
Journal:  Mol Psychiatry       Date:  2016-07-12       Impact factor: 15.992

Review 3.  Drug-induced parkinsonism in the elderly: incidence, management and prevention.

Authors:  José Luis López-Sendón; María Angeles Mena; Justo García de Yébenes
Journal:  Drugs Aging       Date:  2012-02-01       Impact factor: 3.923

4.  Delirium and extrapyramidal symptoms due to a lithium-olanzapine combination therapy: a case report.

Authors:  Cengiz Tuglu; Esin Erdogan; Ercan Abay
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.